GnRH antagonist peptide analog
Ganirelix
Ganirelix is a peptide GnRH antagonist. Its studies distinguish compound exposure, hormone changes and isolated-tissue responses. These are complementary characterization dimensions that cannot be reduced to one potency label.
This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
Hormonal axis, time and response type
Record time and model as well as name. A class label alone does not predict every response of a feedback system.
- Is the entity described as an agonist, antagonist or modulator in the cited assay?
- Are immediate response and adaptation after a different exposure distinguished?
- Is the biomarker a direct receptor readout or a consequence of the whole axis?
Mechanism described in the literature
Clinical literature associates ganirelix with gonadotropin suppression through GnRH antagonism. LH, FSH and estradiol follow different time courses; compound concentration is not any one of those hormonal curves.
Other names in the literature
- Ganirelix
Exposure and response in separate records
An early-phase randomized study measured ganirelix and hormones in female volunteers. Exposure was proportional within the examined range. Maximal LH reduction preceded maximal FSH and estradiol reductions, which coincided at the reported time. This separates pharmacokinetics from endocrine response rather than treating them as one variable.
What the skin model asked
A 2010 investigation compared antagonists in isolated human skin. Ganirelix showed a histamine increase that did not reach statistical significance under the evaluated conditions. The experiment included other compounds and a control for release capacity.
A nonsignificant result has limits
The skin model describes a local tissue response, not event frequency in a population. Lack of significance is not proof of absolutely no effect. Interpretation must retain variability, experimental range and the fact that not all antagonists were tested at identical concentrations.
Questions and answers
Are the ganirelix and LH curves the same?
No. One describes compound exposure and the other a hormone response; they were evaluated separately.
Does the skin assay establish absence of reactions?
No. An ex vivo readout does not establish event frequency in complete organisms.
Sources
- Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. — Fertil Steril, 1999
- Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers.
- Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. — Br J Clin Pharmacol, 2010
- Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples.